TY - JOUR
T1 - Evaluation of the Clinical Course of Endogenous Endophthalmitis
AU - Thompson, Krista N.
AU - Alshaikhsalama, Ahmed M.
AU - Wang, Angeline L.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research to Prevent Blindness, New York, New York. The funding organization had no role in the design or conduct of this research.
Publisher Copyright:
© The Author(s) 2023.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Purpose: To evaluate the presentations, clinical course, treatments, and outcomes of endogenous endophthalmitis cases. Methods: Consecutive medical records from 2016 to 2021 of a county hospital and an academic, private hospital in Dallas, Texas were retrospectively reviewed. This study comprised 37 eyes of 31 patients with endogenous endophthalmitis. Collected data included demographic factors, identifiable risk factors, medical history, presenting symptoms, infectious data, complications, and best-corrected visual acuity (VA) throughout the clinical course. Results: Twenty-two eyes had bacterial endophthalmitis, 7 had fungal endophthalmitis, and 8 had infections that could not be classified. Of the bacterial cases, 5 eyes had panophthalmitis with associated cellulitis. The most common organisms were Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa. The most common presenting symptoms were decreased vision (70%), eye redness (41%), and eye pain (38%). Among all cases, there was no significant difference in the presenting logMAR VA (1.86) before treatment and the most recent logMAR VA (1.75; P =.70) after treatment. However, fungal infections demonstrated better logMAR VA than bacterial infections 6 months after diagnosis (mean logMAR VA, 0.93 vs 2.54, respectively; P =.016) and at most recent follow-up (mean logMAR VA, 0.76 vs 2.3, respectively; P =.004). There was also a strong correlation between presenting VA and most recent VA (r2 = 0.81; P <.01). Conclusions: Visual outcomes of endogenous endophthalmitis cases were poor. Our study found 2 components to be predictive of final VA: (1) whether the infecting organism was bacterial or fungal and (2) a patient’s presenting VA.
AB - Purpose: To evaluate the presentations, clinical course, treatments, and outcomes of endogenous endophthalmitis cases. Methods: Consecutive medical records from 2016 to 2021 of a county hospital and an academic, private hospital in Dallas, Texas were retrospectively reviewed. This study comprised 37 eyes of 31 patients with endogenous endophthalmitis. Collected data included demographic factors, identifiable risk factors, medical history, presenting symptoms, infectious data, complications, and best-corrected visual acuity (VA) throughout the clinical course. Results: Twenty-two eyes had bacterial endophthalmitis, 7 had fungal endophthalmitis, and 8 had infections that could not be classified. Of the bacterial cases, 5 eyes had panophthalmitis with associated cellulitis. The most common organisms were Staphylococcus aureus, Candida albicans, and Pseudomonas aeruginosa. The most common presenting symptoms were decreased vision (70%), eye redness (41%), and eye pain (38%). Among all cases, there was no significant difference in the presenting logMAR VA (1.86) before treatment and the most recent logMAR VA (1.75; P =.70) after treatment. However, fungal infections demonstrated better logMAR VA than bacterial infections 6 months after diagnosis (mean logMAR VA, 0.93 vs 2.54, respectively; P =.016) and at most recent follow-up (mean logMAR VA, 0.76 vs 2.3, respectively; P =.004). There was also a strong correlation between presenting VA and most recent VA (r2 = 0.81; P <.01). Conclusions: Visual outcomes of endogenous endophthalmitis cases were poor. Our study found 2 components to be predictive of final VA: (1) whether the infecting organism was bacterial or fungal and (2) a patient’s presenting VA.
KW - bacterial
KW - endogenous endophthalmitis
KW - endophthalmitis
KW - fungal
KW - infection
KW - visual outcomes
UR - http://www.scopus.com/inward/record.url?scp=85168452765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85168452765&partnerID=8YFLogxK
U2 - 10.1177/24741264231191344
DO - 10.1177/24741264231191344
M3 - Article
C2 - 37706078
AN - SCOPUS:85168452765
SN - 2474-1264
VL - 7
SP - 389
EP - 396
JO - Journal of VitreoRetinal Diseases
JF - Journal of VitreoRetinal Diseases
IS - 5
ER -